MX389312B - Promotores para mejorar la expresion en poxvirus. - Google Patents
Promotores para mejorar la expresion en poxvirus.Info
- Publication number
- MX389312B MX389312B MX2018001055A MX2018001055A MX389312B MX 389312 B MX389312 B MX 389312B MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 389312 B MX389312 B MX 389312B
- Authority
- MX
- Mexico
- Prior art keywords
- poxvirus
- promoters
- expression
- enhance expression
- enhance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199681P | 2015-07-31 | 2015-07-31 | |
| PCT/IB2016/001183 WO2017021776A1 (en) | 2015-07-31 | 2016-07-28 | Promoters for enhancing expression in poxviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001055A MX2018001055A (es) | 2018-05-17 |
| MX389312B true MX389312B (es) | 2025-03-20 |
Family
ID=57068152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001055A MX389312B (es) | 2015-07-31 | 2016-07-28 | Promotores para mejorar la expresion en poxvirus. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11753652B2 (OSRAM) |
| EP (1) | EP3329016B1 (OSRAM) |
| JP (1) | JP6851364B2 (OSRAM) |
| KR (1) | KR102565284B1 (OSRAM) |
| CN (1) | CN107922981B (OSRAM) |
| AU (1) | AU2016303378B2 (OSRAM) |
| CA (1) | CA2990549A1 (OSRAM) |
| DK (1) | DK3329016T3 (OSRAM) |
| ES (1) | ES2901468T3 (OSRAM) |
| IL (1) | IL256869B (OSRAM) |
| MX (1) | MX389312B (OSRAM) |
| RU (1) | RU2753884C2 (OSRAM) |
| SG (1) | SG10202000447YA (OSRAM) |
| WO (1) | WO2017021776A1 (OSRAM) |
| ZA (1) | ZA201800104B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272546B2 (en) | 2017-08-24 | 2024-01-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody |
| SG11202005710YA (en) | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| CA3113818A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| SG11202104918PA (en) | 2018-11-20 | 2021-06-29 | Bavarian Nordic As | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293009B1 (en) | 2019-11-20 | 2025-09-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| IL321887A (en) | 2023-01-12 | 2025-09-01 | Bavarian Nordic As | Recombinantly modified Sarna (vrp) for cancer vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| DK0538496T3 (da) | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| RU2180352C2 (ru) * | 1999-11-24 | 2002-03-10 | Государственный научный центр вирусологии и биотехнологии "Вектор" | ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР |
| EP1601333B1 (en) * | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US20080044377A1 (en) * | 2003-10-15 | 2008-02-21 | Virax Development Pty Ltd | Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine |
| EP2125868B1 (en) * | 2007-02-28 | 2015-06-10 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| CN101775410B (zh) * | 2009-01-09 | 2011-11-16 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种鸡痘病毒载体穿梭质粒及其应用 |
| KR101781966B1 (ko) * | 2009-04-17 | 2017-09-27 | 글로브이뮨 | 암에 대한 병용 면역요법 조성물 및 방법 |
| CN102321637A (zh) * | 2011-09-09 | 2012-01-18 | 中国人民解放军军事医学科学院军事兽医研究所 | 中国鸡痘病毒282e4弱毒株全基因组序列及其应用 |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
-
2016
- 2016-07-28 WO PCT/IB2016/001183 patent/WO2017021776A1/en not_active Ceased
- 2016-07-28 SG SG10202000447YA patent/SG10202000447YA/en unknown
- 2016-07-28 MX MX2018001055A patent/MX389312B/es unknown
- 2016-07-28 KR KR1020187000086A patent/KR102565284B1/ko active Active
- 2016-07-28 AU AU2016303378A patent/AU2016303378B2/en active Active
- 2016-07-28 CN CN201680042251.3A patent/CN107922981B/zh active Active
- 2016-07-28 US US15/747,844 patent/US11753652B2/en active Active
- 2016-07-28 ES ES16775852T patent/ES2901468T3/es active Active
- 2016-07-28 EP EP16775852.3A patent/EP3329016B1/en active Active
- 2016-07-28 RU RU2018106643A patent/RU2753884C2/ru active
- 2016-07-28 DK DK16775852.3T patent/DK3329016T3/da active
- 2016-07-28 IL IL256869A patent/IL256869B/en unknown
- 2016-07-28 CA CA2990549A patent/CA2990549A1/en active Pending
- 2016-07-28 JP JP2018500943A patent/JP6851364B2/ja active Active
-
2018
- 2018-01-05 ZA ZA2018/00104A patent/ZA201800104B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2753884C2 (ru) | 2021-08-24 |
| CN107922981B (zh) | 2022-02-25 |
| RU2018106643A3 (OSRAM) | 2020-01-30 |
| US20180216134A1 (en) | 2018-08-02 |
| KR20180033498A (ko) | 2018-04-03 |
| BR112018002172A2 (pt) | 2018-09-18 |
| AU2016303378B2 (en) | 2021-12-23 |
| HK1254405A1 (en) | 2019-07-19 |
| IL256869A (en) | 2018-03-29 |
| JP2018521651A (ja) | 2018-08-09 |
| MX2018001055A (es) | 2018-05-17 |
| IL256869B (en) | 2022-07-01 |
| JP6851364B2 (ja) | 2021-03-31 |
| SG10202000447YA (en) | 2020-03-30 |
| WO2017021776A1 (en) | 2017-02-09 |
| EP3329016B1 (en) | 2021-10-20 |
| ES2901468T3 (es) | 2022-03-22 |
| EP3329016A1 (en) | 2018-06-06 |
| RU2018106643A (ru) | 2019-08-28 |
| CN107922981A (zh) | 2018-04-17 |
| AU2016303378A1 (en) | 2018-01-25 |
| ZA201800104B (en) | 2022-04-28 |
| BR112018002172A8 (pt) | 2024-02-15 |
| NZ738713A (en) | 2024-11-29 |
| DK3329016T3 (da) | 2022-01-10 |
| US11753652B2 (en) | 2023-09-12 |
| KR102565284B1 (ko) | 2023-08-08 |
| CA2990549A1 (en) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389312B (es) | Promotores para mejorar la expresion en poxvirus. | |
| CO2019013609A2 (es) | Vectores de neoantígeno de alfavirus | |
| MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
| CO2019006541A2 (es) | Administración viral de neoantígenos | |
| MX378913B (es) | Células para inmunoterapia diseñadas para dirigir antígeno presente tanto en células inmunes y células patológicas. | |
| MX2018000845A (es) | Vector vírico orf recombinante. | |
| MX2017009953A (es) | Regulacion de la expresión génica a través de la modulación mediada por un aptámero del empalme alternativo. | |
| MX382223B (es) | Regulacion de expresion genica mediada por nucleasa. | |
| MX2022006513A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| BR112018002600A2 (pt) | células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38 | |
| MX391694B (es) | Elementos regulatorios post-transcripcionales modificados de hepatitis. | |
| CL2017003096A1 (es) | Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis | |
| MX384795B (es) | Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso. | |
| AR103553A1 (es) | Promotor y usos del mismo | |
| GT201500001S (es) | Diseño de carro de juguete (diseño fraccionario de la solicitud no. s-201500001) | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2021009309A (es) | Modulacion de la actividad del complemento. | |
| UY35385A (es) | ?métodos y composiciones para el control de malezas?. | |
| MX387665B (es) | Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos. | |
| GT201600066A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| MX2016013849A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| MX2017008587A (es) | Mirna natural para controlar la expresion de gen y uso del mismo. | |
| CL2018003649A1 (es) | Edición genética mejorada | |
| MX382997B (es) | Composiciones y metodos para mejorar la expresion genetica de pklr. | |
| MX2022012410A (es) | Germinacion de semilla a alta temperatura. |